Golden Analytics | $7,000,000 | (Apr 9, 2026)
HexemBio | $10,400,000 | (Apr 9, 2026)
E2 - Endovascular Engineering | $80,000,000 | (Apr 9, 2026)
T-CURX GmbH
Germany
- Würzburg, Bavaria
- 18/12/2025
- Series A
- $20,000,000
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment.
T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories.
T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.
- Industry Biotechnology Research
- Website https://www.t-curx.com/
- LinkedIn https://www.linkedin.com/company/t-curx/
True Footage | $40,000,000 | (Apr 9, 2026)
Petwealth | $1,700,000 | (Apr 9, 2026)
Pomo | $4,500,000 | (Apr 9, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
GoSats - The simplest onramp to Digital Assets in India | $5,000,000 | (Apr 9, 2026)
Life Biosciences | $80,000,000 | (Apr 9, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)